Shire (LON:SHP)‘s stock had its “outperform” rating restated by research analysts at Credit Suisse Group in a research report issued to clients and investors on Thursday.
Several other research analysts have also issued reports on SHP. Liberum Capital restated a “hold” rating on shares of Shire in a report on Tuesday, July 10th. UBS Group restated a “neutral” rating on shares of Shire in a report on Friday, October 26th. Barclays restated an “equal weight” rating on shares of Shire in a report on Friday, October 19th. Deutsche Bank restated a “buy” rating on shares of Shire in a report on Friday, October 12th. Finally, Berenberg Bank lowered shares of Shire to a “hold” rating and raised their price target for the stock from GBX 4,500 ($58.80) to GBX 5,000 ($65.33) in a report on Thursday, September 6th. Seven research analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and one has given a strong buy rating to the company. The company presently has an average rating of “Buy” and an average price target of GBX 4,725.30 ($61.74).
Shire stock opened at GBX 4,585.50 ($59.92) on Thursday. Shire has a 52-week low of GBX 2,940.50 ($38.42) and a 52-week high of GBX 5,021 ($65.61).
Shire plc, a biotechnology company, researches, develops, licenses, manufactures, markets, distributes, and sells medicines for rare diseases and other specialized conditions worldwide. The company offers products in therapeutic areas, including hematology, genetic diseases, neuroscience, immunology, internal medicine, ophthalmology, and oncology.
Featured Article: Market Capitalization, Large-Caps, Mid-Caps, Small-Caps
Receive News & Ratings for Shire Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire and related companies with MarketBeat.com's FREE daily email newsletter.